ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.0
  1. ホーム
  2. /反応

Water → (E)-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)-1-(5-morpholin-4-yl-indan-1-yl)piperidin-2-one

HRID 1362699
ノート
印刷プレビュー

反応式

HRID 1362699 の反応式
CN(C=O)C.[N:6]1([C:12]2[CH:13]=[C:14]3[C:18](=[CH:19][CH:20]=2)[CH:17]([NH:21][C:22](=[O:43])/[C:23](=[CH:28]/[C:29]2[CH:34]=[CH:33][C:32]([N:35]4[CH:39]=[C:38]([CH3:40])[N:37]=[CH:36]4)=[C:31]([O:41][CH3:42])[CH:30]=2)/[CH2:24][CH2:25][CH2:26]Cl)[CH2:16][CH2:15]3)[CH2:11][CH2:10][O:9][CH2:8][CH2:7]1.[H-].[Na+].O>C(OCC)(=O)C>[CH3:42][O:41][C:31]1[CH:30]=[C:29]([CH:34]=[CH:33][C:32]=1[N:35]1[CH:39]=[C:38]([CH3:40])[N:37]=[CH:36]1)/[CH:28]=[C:23]1/[C:22](=[O:43])[N:21]([CH:17]2[C:18]3[C:14](=[CH:13][C:12]([N:6]4[CH2:7][CH2:8][O:9][CH2:10][CH2:11]4)=[CH:20][CH:19]=3)[CH2:15][CH2:16]2)[CH2:26][CH2:25][CH2:24]/1
参加物実験手順後処理出典と根拠反応ノート

参加物

6

反応物 4

HCID 962WaterHCID 6228DimethylformamideHCID 24758Sodium hydrideHCID 66960274(E)-5-chloro-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)valeric acid (5-morpholin-4-yl-indan-1-yl)amide

生成物 1

HCID 59170680(E)-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)-1-(5-morpholin-4-yl-indan-1-yl)piperidin-2-one収率 81.3%

試薬・触媒・溶媒

1
HCID 8857Ethyl Acetate溶媒

実験手順

To a DMF (5.0 mL) solution of ((E)-5-chloro-2-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)valeric acid (5-morpholin-4-yl-indan-1-yl)amide (2.80 g), sodium hydride (40% mineral oil content, 267 mg) was added at 0° C., and the reaction solution was agitated for 15 minutes. Water and ethyl acetate were added to the reaction solution after confirming disappearance of the starting materials, and the organic layer was partitioned. After the organic layer was washed with a saturated saline solution, it was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. By purifying the obtained residue by silica gel chromatography (elution solvent: a heptane-ethyl acetate system, ethyl acetate-ethanol system), 2.12 g of (E)-3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)benzylidene)-1-(5-morpholin-4-yl-indan-1-yl)piperidin-2-one racemate was obtained. Next, this compound (140 mg) was separated in CHRIALPAK™ AD-H available from Daicel Chemical Industries, Ltd. (2 cm×25 cm mobile phase; ethanol), and the title optically active substance with a retention time of 14 minutes (64 mg; >99% ee) and the title optically active substance with a retention time of 16 minutes (58 mg; >97% ee) were obtained. The physical properties of the title optically active substance with a retention time of 14 minutes are as follows.

後処理

  1. customthe organic layer was partitioned
  2. washAfter the organic layer was washed with a saturated saline solution, it
  3. dry with materialwas dried over anhydrous magnesium sulfate
  4. concentrationconcentrated under reduced pressure
  5. customBy purifying the obtained residue by silica gel chromatography (
  6. washelution solvent

出典と根拠

ORDレコード
ord-d4b0b9f2156d4f839dc5a47054c0d154
出典データセット
uspto-grants-2011_02
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US07880009B2

反応ノート

読み込み中…

このページの内容参加物実験手順後処理出典と根拠反応ノート